What is the difference between germline and somatic testing for Waldenstrom Macroglobulinemia

Germline vs. Somatic Testing in Waldenström Macroglobulinemia

This is an excellent question that highlights an important distinction in how genetic testing works for WM.

The Key Difference

Somatic mutations are changes that occur in cancer cells themselves—they develop during a person's lifetime and are found only in the tumor cells, not in every cell of the body. Germline mutations are inherited changes present in every cell from birth, passed down from parents to children.

What This Means for Waldenström

According to the NCCN Guidelines for Waldenström Macroglobulinemia, the genetic mutations associated with WM are somatic, not germline. This is a critical distinction:

MYD88 L265P Mutation (Most Important)

The NCCN Guidelines emphasize that MYD88 L265P testing should be performed on bone marrow samples using allele-specific polymerase chain reaction (AS-PCR). This mutation is found in approximately 90% of WM patients and is:

• Somatic: It develops in the WM cells themselves, not inherited from parents
• Acquired: It occurs during a person's lifetime as a result of the cancer developing
• Not hereditary: You cannot pass this mutation to your children

CXCR4 Mutation

Similarly, CXCR4 mutations (found in about 40% of WM patients) are also somatic mutations that develop in the cancer cells.

Why This Matters for You

According to the NCCN Guidelines, the fact that WM mutations are somatic means:

1. No family screening needed: Your relatives don't need genetic testing for WM mutations
2. Not inherited: WM is not a hereditary cancer syndrome
3. Specific to tumor cells: Testing focuses on bone marrow samples where WM cells live, not blood or saliva tests for inherited genes
4. Treatment planning: The presence or absence of these somatic mutations helps your oncologist decide which targeted therapies (like BTK inhibitors) may work best for your specific cancer

The Clinical Significance

The NCCN Guidelines note that MYD88 wild-type (meaning no mutation) occurs in less than 10% of WM patients, and importantly, the absence of MYD88 mutation should not be used to exclude a diagnosis of WM if other criteria are met.

Questions to Ask Your Care Team

• Has my bone marrow been tested for MYD88 and CXCR4 mutations?
• How do my specific mutations affect my treatment options?
• Will my family members need any genetic testing or screening?
• How often will these mutations be monitored during my treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.